Jane J Long, Sukhdeep S Sahi, Adley I Lemke, Jie Na, Oscar A Garcia Valencia, Pooja Budhiraja, Hani M Wadei, Vineeth Sudhindran, Roberto Benzo, Matthew M Clark, Meera Shah, David Fipps, Pavel Navratil, Ahmed A Abdelrheem, Afsana A Shaik, Dustin J Duffy, Niv Pencovich, Pankaj Shah, Yogish C Kudva, Aleksandra Kukla, Tayyab S Diwan
OBJECTIVE: Semaglutide, a glucagon-like peptide-1 receptor agonist is approved for weight loss and diabetes treatment, but limited literature exists regarding semaglutide use in patients with advanced chronic kidney disease (CKD). Therefore, this project assessed the safety and efficacy of semaglutide among patients with estimated glomerular filtration rate (eGFR) 15-29 mL/min/1.73 m2 (CKD stage 4), eGFR<15 mL/min/1.73 m2 (CKD stage 5) or on dialysis. METHODS: This is a retrospective electronic medical record based analysis of consecutive patients with advanced CKD (defined as CKD 4 or greater) who were started on semaglutide (injectable or oral)...
July 16, 2024: Endocrine Practice